Company intelligence / Profile preview
Aurigene Oncology
Bangalore, Karnataka, Indiaaurigene.com ↗
- Ownership
- Private
- Employees
- ~425
- Development stage
- Phase 2
01
Overview
The company has 21 programs in global clinical development, including AUR112 (MALT1 inhibitor) in Phase 1 clinical trials in India and AUR101 (RORγt inverse agonist) in Phase 1 clinical trials in Australia. CA-170 has progressed to Phase 2a clinical trials in India.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesCell therapy
- Industry
- Biotech
02
Drug pipeline
27 assets26 more assets in the full pipeline.
Request access →03
Partnerships
ExelixisCurisAgiosEdity TherapeuticsEQRxMitobridge (Astellas)H3 Biomedicine (Eisai)NovartisEndoJanssenMerck SeronoDebiopharmNovo NordiskOrion Pharma
Beyond the preview
Go deeper on Aurigene Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aurigene Oncology.